Lower CD4 Cell Count and Higher Virus Load, but Not Antiretroviral Drug Resistance, Are Associated with AIDS-Defining Events and Mortality: An ACTG Longitudinal Linked Randomized Trials (ALLRT) Analysis

REFERENCES

• Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treat-ment of adult HIV infection — 2008 recommendations of the International AIDS Society-USA Panel. JAMA. 2008;300:555–570.
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretrovi-ral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2008;47:266–285.
   PubMed Web of Science ®Google Scholar
• Deeks SG. Determinants of virological response to antiret-roviral therapy: implications for long-term strategies. Clin Infect Dis. 2000;30:S177–184.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Egger M, Opravil M, et al. Clinical progres-sion and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 1999;353:863–868.
   PubMed Web of Science ®Google Scholar
• Hogg RS, Bangsberg DR, Lima VD, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006;3:e356;1570–1578.
   Google Scholar
• Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS. 2008;22:2097–2106.
   PubMed Web of Science ®Google Scholar
• Eron JJ Jr, Park JG, Haubrich R, et al. Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (Pis) in human immunodeficiency virus-infected subjects failing prior PI therapy. Antimicrob Agents Chemother. 2009;53:2335–2341.
   PubMed Web of Science ®Google Scholar
• Anderson JA, Jiang H, Ding X, et al. Genotypic suscepti-bility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection. AIDS Res Hum Retrovituses. 2008;24:685–694.
   PubMed Web of Science ®Google Scholar
• Vray M, Meynard JL, Dalban C, et al. Predictors of the virological response to a change in the antiretroviral treat-ment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standards of care (Nervel trial, ANRS 088). Antivir Ther. 2003;8:427–434.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009. http://aidsinfo.nih.gov.
   Google Scholar
• Aberg JA, Kaplan JE, Libman H, et al. Primary care guide-lines for the management of persons infected with human immunodeficiency virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651–681.
   PubMed Web of Science ®Google Scholar
• Martinez-Picado J, Martinez MA. HIV-1 reverse transcrip-tase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 2008;134:104–123.
   PubMed Web of Science ®Google Scholar
• Dykes C, Demeter LM. Clinical significance of HIV type 1 replication fitness. Clin Micro Rev. 2007;20:550–578.
   PubMed Web of Science ®Google Scholar
• Chin BS, Choi J, Nam JG, et al. Inverse relationship between viral load and genotypic resistance mutations in Korean patients with primary HIV type 1 infections. AIDS Res Hum Retroviruses. 2006;22:1142–1147.
   PubMed Web of Science ®Google Scholar
• Castagna A, Danise A, Menzo S, et al. Lamivudine mono-therapy in HIV-1-infected patients harbouring a lamivu-dine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20(6):795–803.
   PubMed Web of Science ®Google Scholar
• Jiang H, Deeks SG, Kuritzkes DR, Lallemant M, Katzen-stein D, Albrecht M, DeGruttola V. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis. 2003;188:1001–1008.
   PubMed Web of Science ®Google Scholar
• HIV Drug Resistance Database. Stanford University. http://hivdb.stanford.edu/index.html.
   Google Scholar
• Swindells S, Evans S, Zackin R, et al. Predictive value of HIV-1 viral load on risk for opportunistic infection. J Acquir Immune Defic Syndr 2002;30:154–158.
   PubMed Web of Science ®Google Scholar
• Recsky MA, Brumme ZL, Chan KJ, et al. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral ther-apy. J Infect Dis. 2004;190:285-292. Epub June 11, 2004.
   PubMed Web of Science ®Google Scholar
• Lucas GM, Gallant JE, Moore RD. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing. AIDS. 2004;18:1539–1548.
   PubMed Web of Science ®Google Scholar
• Cozzi-Lepri A, Phillips AN, Clotet B, et al. Detection of HIV drug resistance during antiretroviral treatment and clini-cal progression in a large European cohort study. AIDS. 2008;22(16):2187–2198.
   PubMed Web of Science ®Google Scholar
• Kozel MJ, Hullsiek KH, Macarthur RD, et al. The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral naive participants started on 3 different antiretroviral therapy strategies. HIV Clin Trials. 2007;8:357–370.
   PubMed Web of Science ®Google Scholar
• Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med. 1999;130:570–577.
   PubMed Web of Science ®Google Scholar
• Katzenstein D, Hughes M, Albrecht M, et al. Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. AIDS Res Hum Retroviruses. 2001;16: 1031–1037.
   Web of Science ®Google Scholar
• Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223–231.
   PubMed Web of Science ®Google Scholar
• Ho SK, Coman RM, Bunger JC, et al. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and pg(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology. 2008;378:272–281.
   PubMed Web of Science ®Google Scholar
• Ross L, Parkin N, Lanier R. Short communication: The number of HIV major NRTI mutations correlates directly with other antiretroviral-associated mutations and indi-rectly with replicative capacity and reduced drug suscepti-bility. AIDS Res Hum Retroviruses. 2008;24:617–620.
   PubMed Web of Science ®Google Scholar
• Murphy RL, Gulick RM, DeGruttola V, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lami-vudine in adults with human immunodeficiency virus infec-tion. AIDS Clinical Trials Group 347 Study Team. J Infect Dis. 1999;179:808–816.
   PubMed Web of Science ®Google Scholar
• Albrecht M, Bosch R, Hammer S, et al. Nelfinavir, efavi-renz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001;345:398–407.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Ribaudo H, Bassett R, et al. A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials. 2010;11: 312–324.
   PubMed Web of Science ®Google Scholar
• Robbins GK, DeGruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293–2303.
   PubMed Web of Science ®Google Scholar
• Fischl MA, Ribaudo HJ, Collier AC, et al. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis. 2003;188:625–634.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002;288:169–180.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Gilbert PB, Bennett K, et al. Effects of treat-ment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS. 200115: 1379–1388.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucle-oside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850–1861.
   PubMed Web of Science ®Google Scholar